OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Equity Capital Raises
Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
Week ended 12/23/2022
Week ended 12/23/2022
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Week ended 12/23/2022
The Week’s Largest Closed Equity Transaction:
- On December 20, 2022, Gilgamesh Pharmaceutics (Private), a “next-generation” psychedelics company, closed a $39M Series B Funding Round.
- Proceeds will support the progress of two programs currently in Phase 1 Clinical trials testing safety and efficacy, along with continued development of preclinical pipeline programs.
- Investors led by Prime Movers Lab included Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital, and Gron Ventures.
- Gilgamesh focuses on novel drugs that mimic the effects of well-known psychedelics while being easier to patent.
- The company’s initial compounds are short-acting and have mild to no hallucinogenic effects.
Public vs. Private Raises:
- Seven of the eight companies that raised capital this week were public. All trade in Canada (four on the CSE and three on TSX) and in the U.S. on OTC.
Equity vs. Debt Cap Raises:
- Equity accounted for 28.5% of this week’s capital raises.
Week ended 12/23/2022
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Weekly Valuation Tracker
Viridian highlights a specific industry sector and provides a deep dive into valuation metrics and comparable company valuations for public companies operating in that sector. The Weekly Valuation Tracker provides proprietary, actionable valuation data.
- Week ended 12/23/2022
This week’s valuation tracker focuses on the 7 U.S. MSOs with market cap over $500M in the Viridian Value Tracker database in gauge the valuation impact of the 2nd earnings that have been released so far, Green Thumb (GTII: CSE), Curaleaf (CURA: CSE), and Trulieve.
- Week ended 12/23/2022
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.